Trade with Eva: Analytics in action >>

Tuesday, July 14, 2020

-=Rigel Pharma (RIGL) initiates a COVID-19 trial


Rigel Pharma and Imperial College London initiates two-stage trial to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia


Announced the initiation of an investigator-sponsored trial being conducted by Imperial College London to evaluate the efficacy of oral SYK inhibitor fostamatinib for the treatment of COVID-19 pneumonia. The primary objective of the two-stage trial, which is to be supported by co and Novartis (NVS), will be to determine the efficacy of fostamatinib and of ruxolitinib vs standard of care.

No comments:

Post a Comment